Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

PMID:
20519267
2.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
3.

The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.

Giglio N, Micone P, Gentile A.

Vaccine. 2011 Sep 14;29 Suppl 3:C35-42. doi: 10.1016/j.vaccine.2011.06.095. Review.

PMID:
21896351
4.

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

Beutels P, Thiry N, Van Damme P.

Vaccine. 2007 Feb 9;25(8):1355-67. Epub 2006 Nov 3. Review.

PMID:
17208339
5.

Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.

Saokaew S, Rayanakorn A, Wu DB, Chaiyakunapruk N.

Pharmacoeconomics. 2016 Dec;34(12):1211-1225. Review.

PMID:
27510721
6.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

7.

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.

Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR.

Expert Rev Vaccines. 2012 Oct;11(10):1235-47. doi: 10.1586/erv.12.99. Epub 2012 Nov 21. Review.

PMID:
23170992
8.

Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.

Dinleyici EC, Yargic ZA.

Expert Rev Vaccines. 2009 Aug;8(8):977-86. doi: 10.1586/erv.09.68. Review.

PMID:
19627181
9.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
10.

Pneumococcal vaccination policy in Europe.

Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P.

Euro Surveill. 2005 Sep;10(9):174-8. Review.

PMID:
16280609
11.

Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).

Wu DB, Chaiyakunapruk N, Chong HY, Beutels P.

Vaccine. 2015 Mar 30;33(14):1633-58. doi: 10.1016/j.vaccine.2015.01.081. Epub 2015 Feb 11. Review.

PMID:
25681663
12.

Pneumococcal conjugate vaccines for preventing otitis media.

Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder AG, Sanders EA.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001480. doi: 10.1002/14651858.CD001480.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;4:CD001480.

PMID:
19370566
13.

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

van de Vooren K, Duranti S, Curto A, Garattini L.

Pharmacoeconomics. 2014 Jan;32(1):29-45. doi: 10.1007/s40273-013-0113-y. Review.

PMID:
24288207
14.

Recent advances in pneumococcal vaccination of children.

Russell FM, Mulholland EK.

Ann Trop Paediatr. 2004 Dec;24(4):283-94. Review.

PMID:
15720885
15.

Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines.

De la Hoz-Restrepo F, Castañeda-Orjuela C, Paternina A, Alvis-Guzman N.

Vaccine. 2013 Jul 2;31 Suppl 3:C80-7. doi: 10.1016/j.vaccine.2013.05.064. Review.

PMID:
23777697
16.

Evaluating the costs and benefits of pneumococcal vaccination in adults.

Porchia BR, Bonanni P, Bechini A, Bonaccorsi G, Boccalini S.

Expert Rev Vaccines. 2017 Feb;16(2):93-107. doi: 10.1080/14760584.2017.1242419. Epub 2016 Oct 12. Review.

PMID:
27680425
17.

Effectiveness of 2+1 PCV7 vaccination schedules in children under 2 years: a meta-analysis of impact studies.

Schönberger K, Kirchgässner K, Riedel C, von Kries R.

Vaccine. 2013 Dec 5;31(50):5948-52. doi: 10.1016/j.vaccine.2013.10.042. Epub 2013 Oct 19. Review.

PMID:
24144469
18.

The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults.

Frenck RW Jr, Yeh S.

Expert Opin Biol Ther. 2012 Jan;12(1):63-77. doi: 10.1517/14712598.2012.636348. Epub 2011 Nov 10. Review.

PMID:
22074323
19.
20.

Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers.

Whitney CG, Goldblatt D, O'Brien KL.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S172-81. doi: 10.1097/INF.0000000000000076. Review.

Supplemental Content

Support Center